Investors & Media Press Releases Investor Relations Overview Corporate Governance Press Releases & Statements Events & Presentations SEC Filings Annuals and Proxies Investor FAQs Financials & Filings Stock Information Analyst Coverage Email Alerts Subscription Notice of Pendency of Settlement of Action Press Releases Items Per Page 102550 Year None20242023202220212020201920182017 Date Title View Toggle Summary October 17, 2024 Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio Toggle Summary October 15, 2024 Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 Toggle Summary October 8, 2024 Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease Toggle Summary September 26, 2024 Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program Toggle Summary July 31, 2024 Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress Toggle Summary July 24, 2024 Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor Toggle Summary July 17, 2024 Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 Toggle Summary June 11, 2024 Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease Toggle Summary June 5, 2024 Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference Toggle Summary May 7, 2024 Sage Therapeutics to Participate in Upcoming May Investor Conferences Sage Therapeutics to Participate in Upcoming May Investor Conferences Pagination Current page 1 Page 2 Page 3 Next page Next Last page Last Displaying 1 - 10 of 21
Press Releases Items Per Page 102550 Year None20242023202220212020201920182017 Date Title View Toggle Summary October 17, 2024 Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio Toggle Summary October 15, 2024 Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 Toggle Summary October 8, 2024 Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease Toggle Summary September 26, 2024 Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program Toggle Summary July 31, 2024 Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress Toggle Summary July 24, 2024 Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor Toggle Summary July 17, 2024 Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 Toggle Summary June 11, 2024 Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease Toggle Summary June 5, 2024 Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference Toggle Summary May 7, 2024 Sage Therapeutics to Participate in Upcoming May Investor Conferences Sage Therapeutics to Participate in Upcoming May Investor Conferences Pagination Current page 1 Page 2 Page 3 Next page Next Last page Last Displaying 1 - 10 of 21
